Further analyses are required on the potential impact on plasma IP-10 and MIG and subsequent chronic immune dysfunction of new ART regimens, including dolutegravir-based two-drug regimens and long-acting formulations, as well as in people with persistent immune discordance. Here, CXCL10 is linked to immune system disorder.